All In Biotech

Drug Trial Radar · NCT06110338

Safety and Tolerance Study of IBI355 in Health Volunteers

A Phase 1, Double-blind Study to Evaluate the Safety and Tolerability of a Single-dose Administration of IBI355 in Health Adults

Last checked: Nov 19, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Oct 30, 2023

Primary completion

Sep 20, 2024

Study completion Sep 23, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being done to find out if IBI355 is safe and tolerance in health volunteers. The study will test increasing single doses of IBI355 given to adult health volunteers. The goal is to confirmed the safety of the highest dose of IBI355 or to find out the highest dose of IBI35 that can be given to health volunteer that dose not cause unacceptable side effects. Different dose regimens will be evaluated. The pharmacokinetics and ADA of IBI355 will also be evaluated.

Conditions

  • Healthy Subjects

Interventions

  • placeboDrug

    placebo iv. once.

  • IBI355Drug

    IBI355 iv. once.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AE、SAE after receiving IBI 355Time frame: week 0-12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aerospace Center Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.